Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if elacestrant alone or with abemaciclib works well against endometrial cancer. The people in this study have endometrial cancer that has spread or come back. Their cancers have a protein called the estrogen receptor (ER) and they have a normal version of the p53 gene. This gene stops cancer from growing.
Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body's normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
In this study, researchers are assessing the safety and effectiveness of giving the drug disitamab vedotin alone and in combination with pembrolizumab immunotherapy in people with inoperable or metastatic urothelial cancers that make too much of the HER2 protein. Disitamab vedotin targets and kills cancer cells with the HER2 protein. Pembrolizumab boosts the power of the immune system to detect and destroy cancer cells.
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient's stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient's immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
This clinical trial explores a novel approach to treating mantle cell lymphoma (MCL). Researchers are integrating targeted agents into standard induction and maintenance chemoimmunotherapy.  The people in this study have MCL that has not yet been treated.
